Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine-Reference-Cited by-同舟云学术

Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine

Published:2022 Issue:1 Volume:65 Page:63-69
ISSN:1346-8049
Container-title:Yonago Acta Medica
language:en
Short-container-title:Yonago Acta Med.

Author:

Okada Shinichi¹,Tomita Katsuyuki²,Inui Genki²,Ikeuchi Tomoyuki²,Touge Hirokazu²,Hasegawa Junichi³,Yamasaki Akira⁴

Affiliation:

1. Department of Pediatrics, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan

2. Department of Respiratory Medicine, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan

3. Department of Internal Medicine, National Hospital Organization Yonago Medical Center, Yonago 683-0006, Japan

4. Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan

Publisher

Tottori University Faculty of Medicine

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/yam/65/1/65_2022.02.012/_pdf

Reference22 articles.

1. 1. Novelli G, Biancolella M, Mehrian-Shai R, Erickson C, Pollitt KG, Vasilion V, et al. COVID-19 update: the first 6 months of the pandemic. Hum Genomics. 2020;14:48. DOI:10.1186/s40246-020-00298-w

2. 2. Coronavirus disease (COVID-19) pandemic [Internet]. Worldometer [cited 2021 Jul 9]. Available from: https://www.worldometers.info/coronavirus/?#countries

3. 3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15. PMID:33301246, DOI:10.1056/NEJMoa2034577

4. 4. Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376-81. PMID:33866000, DOI:10.1016/j.ijid.2021.04.047

5. 5. Pfizer-BioNTech COVID-19 vaccine overview and safety [Internet]. Atlanta: Centers for Disease Control and Prevention [cited 2021 Jul 7]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Febrile Reactions Associated with High IgG Antibody Titers after the Second and Third BNT162b2 Vaccinations in Japan;Japanese Journal of Infectious Diseases;2023-09-30

2. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study;Frontiers in Immunology;2023-04-19

3. Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens;eBioMedicine;2022-10